Popularization of traditional and complementary medicine: Urging voluminous effort driving towards scientific evaluation of safety and efficacy

Popularization of traditional and complementary medicine: Urging voluminous effort driving towards scientific evaluation of safety and efficacy

Papiya BigoniyaInternational Journal of Traditional and Complementary Medicine

Principal, Radharaman College of Pharmacy, Ratibad, Bhopal, 462002, M.P., India

Traditional medicines are widely used in developing countries with fast gaining popularity all over the world. Traditional medicine practices has long historical background that passes on from generation to generation. The quantity and quality, safety and efficacy of traditional medicine has became a worldwide concern emphasizing the need to develop harmonized international standards. The global market for herbal remedies is about $83 billion and growing at 10 to 20 percent yearly with the top global players like Germany, Asia, Japan, Europe and North America.
Traditional therapies have a popular perception lower adverse effects rate as consumers perceive that natural sourced products are less likely to cause problems. The common causes of herbal product related adverse reaction occurrence are use toxic herbs, overdose, drug–herb interactions and idiosyncratic reactions. Herbal are mostly used over the counter without knowledge or advice of practitioner rising safety concern. Quality issues of traditional products are due to improper processing, adulteration, misidentification, missing of one or more herbs in a product, substitution, inclusion of prescription drugs, contamination and variability in active ingredient. Scientific study to assess safety and efficacy, composition, dosage form requirements are need of the time.
Regulations governing the safety, quality and efficacy of traditional and complementary therapies vary widely from country to country and many countries do not have formal system for traditional and complementary medicine registration. Implementation of good manufacturing practice in cultivation, harvesting and processing along with chromatographic fingerprinting will greatly contribute to quality control of traditional medicines. Rigorous research is required for preclinical safety-efficacy, toxicology and clinical trials of traditional and complementary medicine. Boosting research with availability of funds are a major issue. Credibility of traditional and complementary will depend on development of evidence base approval system by encouraging spontaneous reporting, implementing active pharmacovigilance and clinical safety monitoring system.

Keywords:  Traditional medicine, Complementary medicine, Scientific evaluation of safety and efficacy.

Free Full-text PDF

How to cite this article:
Papiya Bigoniya. Popularization of traditional and complementary medicine: Urging voluminous effort driving towards scientific evaluation of safety and efficacy. International Journal of Traditional and Complementary Medicine 2016; 1:2. DOI:10.28933/bigoniya-ijtcm-2016

1. Essential medicines and health products. http://www.who.int/medicines/areas/traditional/en/.
2. WHO traditional medicine strategy: 2014-2023. http://apps.who.int/iris/bitstream/10665/92455/1/9789241506090_eng.pdf
3. General guidelines for methodologies on research and evaluation of traditional medicine. http://apps.who.int/iris/bitstream/10665/66783/1/WHO_EDM_TRM_2000.1.pdf.
4. Hanssen B, Grimsgaard S, Launso I, Fonnebo V, Falkenberg T, Rasmussen NKR (2005). Use of complementary and alternative medicine in the Scandinavian countries. Scandinavian Journal of Primary Health Care 23(1): 57–62.
5. The global herbs and botanicals market. http://www.nutraceuticalsworld.com/issues/2008-07/view_features/the-global-herbs-amp-botanicals-market.
6. Fraenkel l, Bogardus Jr. ST, Concato J, Wittink DR (2004). Treatment options in knee osteoarthritis: The patient’s perspective. Archives of Internal Medicine 164(12): 1299–304.
7. Stevinson C, Huntley A, Ernst E (2002). A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 25: 251–61.
8. Ang-lee M, Moss J, Yuan C (2001). Herbal medicine and perioperative care. Journal of the American Medical Association 286: 208–16.
9. Newman DJ1, Cragg GM (2007). Natural products as sources of new drugs over the last 25 years. Journal of Natural Product 70(3): 461–77.
10. Supplements. http://www.consumerlab.com/reviews/Red_yeast_ Rice_Supplements-lovastatin_Monacolin/Red_yeast_Rice/
11. Huang WF, Wen KC, Hsaio MI (1997). Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. Journal of Clinical Pharmacology 37: 224–350.
12. Ko R (1998). Adulterant in Asian patent medicines. New England Journal of Medicine 339(12): 839–41.
13. U.S. Food and Drug Administration. (2009). FDA’s MedWatch safety alerts. Rockville, U.S. Department of Health and Human Services. http://www.fda.gov/forConsumers/ ConsumerUpdates/ucm192103.htm.
14. Traditional and complementary medicine policy. (2012). MDS-3: Managing Access to Medicines and Health Technologies, Chapter 5. http://apps.who.int/medicinedocs/en/d/Js19582en/.
15. Bast A, Chandler RF, Choy PC, Delmullel M, Gurenwald J, Halkes BA, Keller K, et al., (2002). Botanical health products, positioning and requirements for effective and safe use. Environmental Toxicology and Pharmacology 12: 195–211.
16. WHO traditional medicine strategy: 2002-2005. http://www.wpro.who.int/health_technology/book_who_traditional_medicine_strategy_2002_2005.pdf.
17. European Medicines Agency. Herbal medicinal products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000208.jsp.
18. Indian Pharmacopoeia (2010). 6th Edition. Ministry of Health and Family Welfare. Government of India.
19. Ernst E, Pittler MH, Stevinson C, et al., (2001). The desktop guide to complementary and alternative medicine: An evidence-based approach. Journal of Royal Society of Medicine 94(12): 650–1.
20. Li GQ, Roufogalis BD (2003). The quality and safety of traditional Chinese medicines. Australian prescriber 26:128–301.
21. Vickers A, Cassileth B, Ernst E, et al., (1997). How should we research unconventional therapies? A panel report from the conference on complementary and alternative medicine research methodology, National Institute of Health. International Journal of Technology Assessment and Health Care 13: 111–21.
22. Ernst E (1999). Funding research into complementary medicine: the situation in Britain. Complementary Therapies in Medicine 7: 250–3.